Sarah C. Stallings

TL;DR: The level of risk experienced by cancer patients who participate in phase 1 treatment trials appears to have improved over the 12-year period from 1991 through 2002, and the ratio of risk to benefit may have also improved.

TL;DR: The design and initial implementation of the eMERGE‐PGx project is described, including site‐specific project implementation and anticipated products, including genetic variant and phenotype data repositories, novel variant association studies, clinical decision support modules, clinical and process outcomes, approaches to managing incidental findings, and patient and clinician education methods.

TL;DR: There was low concordance in designating SCN5A and KCNH2 variants as pathogenic in individuals recruited for nonantiarrhythmic drug exposure phenotypes, and these findings raise questions about the implications of notifying patients of incidental genetic findings.

TL;DR: The distribution and scope of genetic variation in relevant pharmacogenes are highlighted, identifying challenges associated with implementing clinical sequencing for drug treatment at a broader level, and underscoring the importance for multifaceted research in the execution of precision medicine.

TL;DR: The structure of U2A, a 20-base analogue of stem loop IIa from Saccharomyces cerevisiae, is solved using NMR and restrained molecular dynamics and the efficacy of a new structure calculation protocol, torsion angle molecular dynamics, is demonstrated.